{"schema_version":"secwatch.filing_event.v1","accession":"0001649094-26-000045","form_type":"8-K","ticker":"PCVX","cik":"0001649094","company_name":"Vaxcyte, Inc.","filed_at":"2026-09-03T20:18:54+00:00","discovered_at":"2026-09-03T20:21:10.260620+00:00","generated_at":"2026-09-03T20:21:26.552502+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vaxcyte appoints CMO and CLO; narrows VAX-31 OPUS-1 topline data to end of October 2026","bullets":["Luis Jodar, Ph.D., former Pfizer CMO for Vaccines and Infectious Diseases, joins as Chief Medical Officer.","David McAvoy, J.D., former Teva Chief Legal Officer, joins as Chief Legal Officer; Mikhail Eydelman remains SVP, General Counsel.","Topline safety, tolerability, and immunogenicity data from VAX-31 Phase 3 OPUS-1 trial now expected by end of October 2026, narrowing prior Q4 guidance.","Jodar led clinical development and medical affairs for Prevnar 13 and Prevnar 20 at Pfizer."],"urls":{"canonical":"https://secwatch.observer/filing/0001649094-26-000045","json":"https://secwatch.observer/filing/0001649094-26-000045.json","markdown":"https://secwatch.observer/filing/0001649094-26-000045.md","text":"https://secwatch.observer/filing/0001649094-26-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/0001649094-26-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/pcvx-20260831.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-03T20:21:26.552502+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}